Authors-guidelines publish research paper in international journals
How to share your research article to increase the impact of your research
“ How to publish a paper in the Research Leap ”
Publishing guidelines for authors – The International Journal of Management Science and Business Administration – ISSN 1849-5664 (ONLINE) – ISSN 1849-5419 (PRINT)
The journal is submitted by clicking on the SUBMIT YOUR PAPER icon
– Click on the SUBMIT YOUR PAPER link which will take you through to the Journal Submission page
– Prepare your paper according to the Guide for Authors
– Submit your paper to our e-mail: ijmsba@researchleap.com
International Journal of Management Science and Business Administration articles are open-access, available to subscribers and public alike with the permission to reuse. There is no subscription fee to access the articles. The funding comes from the authors themselves.
The articles of the International Journal of Management Science and Business Administration are available free of charge both to individual users and organizations. This means users can read, download, copy, share, print out, or reference to the texts of the journal without having to get permission from the authors or publishers.
The fee for the open-access publication is paid either by authors themselves or their funder.
The publication charge of International Journal of Management Science and Business Administration is 115 USD for online publication only or 175 USD for online publication + 2 hard copies. For additional copies, the charge is 15 USD per issue.
Direct payment using Paypal and credit cards can be made through the website. The detailed information on the payment process, including the bank transfer option, will be sent to the corresponding author email.
In the reviewing process, a paper is initially reviewed either by an editor or a co-editor. Next, if the editor/co-editor finds it suitable for publication, they send it to two other referees for peer-review. The review is double-blind peer review. Provided the referees approve the paper, the editor eventually has the final say about whether the article should be published as it is, amended, or rejected altogether.
It is of utmost importance that the articles for the journal have not been published before in the present or almost the same form, or they are being considered for publication in another journal. The journal can publish papers that were previously published in conference proceedings under the condition that the publication does not infringe upon the rights of the conference proceedings publisher. The authors of the paper must make sure that their work does not go against existing copyright as well as ensuring the paper will compensate for the publisher in case of a warranty breach. Unless agreed differently, the papers, as well as contributions, become the legal copyright of the journal so that the dispersion and proper use of them are facilitated. Authors should refer to ideas and findings of other authors of by proper citing of literature, referencing, such as using clear indented text or quotation marks and using APA style formatting.
The requirements of our platform are as follows:
While using tables, charts or excerpts, exceeding four hundred words, from a different source, the followings must be taken into account.:
Before using the content (even freely available online), authors must check the website for more details of the copyright owners as well as getting their permission.
It should be noted that prior to the publication, the proofs are not supplied. It is the journal which considers the final version of the paper. However, it is the responsibility of the author to check the article for completeness, grammatical, spelling, and typographical errors. publish research paper in international journals
Microsoft Word (DOC, DOCX) is suitable for the final manuscript document.
All the manuscripts submitted to Research Leap must be split into the sections in the following order: Make sure you use the following guidelines while preparing your manuscript for submission:
It is imperative that all the files are submitted as a Word document | |
Including the references and appendices, the articles must be no fewer than 3000 words but not exceed 9000. | |
The title should not exceed ten words in total | |
Using a special template, an Article Title Page ought to be submitted together with the article. The template should include the following: § Title of the article § Details of the author (see below) § Acknowledgements § Biographies of authors § Structured Abstract (see below) § Keywords (see below) § Classification of the article | |
The Article Title Page must include the followings: | |
An author should provide an abstract on the Article Title Page containing: § The objective (mandatory) § Design/methodology/approach (mandatory) § Outcomes (mandatory) § Limitations and implications of the research (optional) § Practical implications (optional) § Social implications (optional) § Originality or/and value (mandatory) Including keywords and article classifications, the word count should not exceed 300. | |
The Article Title Page should contain no more than ten keywords recapping the main topics of the research. Although the editorial team of the journal will try to keep the keywords in the publication, those might be changed or replaced with different terms to ensure consistency. | |
Authors must ensure their paper on the Article Title Page falls under one of the following categories: § Empirical study § Hypotheses and theory § Case study § Literature review. | |
Conciseness of the headings must be ensured with clear differentiation between the order of headings. Ideally, the first level headings are written in bold format and sub-headings in medium italics. | |
When it is absolutely essential, notes or endnotes might be used, being demonstrated in the text by consecutive numbers, in square brackets, and illustrated at the end of the paper. | |
In the acknowledgement section, authors must declare the sources of outer research funding with a statement. The role of the funder/financial sponsor must be described from the beginning of the study design to submission, | |
All the figures, including graphs, diagrams, web pages, and photographic images, ought to be submitted in an electronic form. Quality and legibility of the figures must be ensured with being numbered in order with Arabic numerals. In order to ease the appearance of the graphics on the online database, they might be provided in color. § All figures made in MS Word, MS PowerPoint, MS Excel have to be provided in their original form. If the figures are created in other formats, they must be copied and pasted into a new MS Word page or saved and then imported into an MS Word document. Alternatively, a .pdf format can be created from the software of origination. § In case the figures cannot be provided in the above-mentioned formats, they can be accepted in .pdf, .ai, and .eps. Again, if these formats are impossible to use, then you can submit the figures in tif, .jpeg, or .bmp at a minimum of 10cm wide and a resolution of 300dpi. § While preparing web pages or screenshots, screenshot the image and paste it into a new Microsoft Word page using the “Alt” + “Print Screen” (or “Ctrl” + “Print Screen” if you want to screenshot all the contents of the screen) and “Ctrl”+”V.” The photographic images have to be saved as .tif or .jpeg files of at least 10cm wide and at a resolution of minimum 300dpi. They also ought to be supplied in an electronic form with high quality. To ensure that, you can set your camera settings at the highest quality and resolution. | |
When tables are used, they should be clearly labeled in the text body with the labels as legible as possible. In addition, superscripts and asterisks must be illustrated next to the items they refer to and have corresponding descriptions illustrated as footnotes. | |
In order to enable the readers to use Reference Linking facility on the database and refer back to the cited works via CrossRef, your references have to be in APA style written completely, accurately, and consistently. Cited texts should be in the following forms: § Using the first-named author’s name: § Using two names: § When there are more than two authors: You must use a reference list at the end of your paper in alphabetical order. | |
Surname, Initials (year), , Place of publication, Publisher.e.g. Barney, J. B., & Hesterly, W. S. (2010). (pp. 4-25). Upper Saddle River, NJ: Prentice Hall. | |
Surname, Initials (year), Chapter title, In Editor’s Initials, Surname, , Publisher, pp. pages of chapter, Publisher, e.g. Calabrese, F. A. (2005). The early pathways: Theory to practice—A continuum. In (pp. 15-50). Butterworth-Heinemann. | |
Surname, Initials (year), Title of article, , volume, number, pages.e.g. Bekmurodova, G. (2020). Theoretical Features of FDI (Foreign Direct Investment) and its Influence to Economic Growth. , (2), 33-39. | |
Surname, Initials (year of publication), Title of paper, in , volume, (pp. page number). Publisher, Place of Publication e.g. Weinstein, A., & Pohlman, R. A. (2015). Customer value: a new paradigm for marketing management. In (pp. 132-133). Springer, Cham. | |
Surname, Initials (year). Title of paper, paper presented at , , available at: URL if freely available on the internet (accessed date).e.g. Aumueller, D. (2005, May). Semantic authoring and retrieval within a Wiki. In ., available at: (accessed 20 February 2007). | |
Surname, Initials (year). . working paper [number if available], Institution or organization, Place of organization, date e.g. Moizer, P. (2003). . working paper, Leeds University Business School, University of Leeds, Leeds, 28 March. | |
Editor, A., & Editor, B. (Eds.). (Date). Dictionary/Encyclopedia entry. In (edition, if not the first). Publisher. e.g. Hughes, J. M., Michell P. A., & Ransom, W. S. (Eds.). (1992). Zucchini. In (2nd ed.). Oxford University Press. | |
Surname, Initials. (date). Article title. , pages. e.g. Smith, A. (January 21, 2008). Money for old rope. , pp. 1, 3-4. | |
(date). , pages. e.g. Small change , p. 7. | |
If available online, the full URL should be supplied at the end of the reference, as well as a date that the resource was accessed.e.g. Castle, B. (2005). . Name of the Website, available at: (accessed 12 November 2007).Standalone URLs, i.e. without an author or date, should be included either within parentheses within the main text, or preferably set as a note (roman numeral within square brackets within text followed by the full URL address at the end of the paper). |
The editor of journals of Research Leap platform is solely responsible for deciding which articles submitted to the journal shall be published. To reach this decision, the editor is guided by policies of the journal’s editorial board and constrained by such legal requirements in force regarding libel, copyright infringement, and plagiarism. Published articles should remain extant, exact and unaltered as far as is possible. However, there may arise some occasional circumstances when published article must be later retracted or even removed. All these actions mentioned above can take place under exceptional circumstances.
Crossmark is a multi-publisher initiative from Crossref to provide a standard way for readers to locate the current version of a piece of content. By applying the Crossmark logo, Research Leap is committing to maintaining the content it publishes, and to alerting readers to changes if and when they occur.
Clicking on the Crossmark logo will tell you the current status of a document, and may also give you additional publication record information about the document.
Article withdrawal is only applicable for articles which were previously published in the other journals or accidently submitted twice. In most cases, articles may represent serious issues including infringements of professional ethical codes, such as multiple submission, plagiarism, and fraud usage of data. The withdrawal process is also applicable to articles which are in press (under consideration to be published in the other journals) that has different errors, or duplications of articles published in other journals are considered to be “withdrawn” from Research Leap. Withdrawn indicates that content of articles such as HTML and PDF is removed and replaced with HTML page and PDF simply mentioning that the article has been withdrawn according to Research Leap Policy on Article in Press Withdrawal with a link to the current policy document.
Infringement of academic and professional ethical codes includes multiple submission, plagiarism, fraudulent use of data. The retraction will be mainly used to correct publication and submission errors. Retraction of an article will be done by the author or the editor based on the advice of members of the scholarly community. Number of scholarly bodies has developed the standards dealing with retractions, and best of these retractions are adopted for article retraction by Research Leap:
It may be required to remove an article from the online database only in the extremely limited number of cases. This type of article removal will occur under the following circumstances:
In these cases, the article will be removed due to the legal reasons where only the information on metadata such as Title and Authors will remain. publish research paper in international journals
When the article poses a severe health risk, the authors of the original article will be obliged to retract the flawed content and replace it with the corrected version. In these cases, the procedures for retraction will be followed with the difference that the database retraction will publish a link to the corrected re-published article and a history of the document. publish research paper in international journals
publish research paper in international journals
An official website of the United States government
Here’s how you know
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
June 14-15, 2024 Montreal, Canada
After three years of virtual meetings, the 2024 NIDA International Forum returned to an in-person format. The meeting, which was held on June 14 and 15 in Montreal in conjunction with the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting, was cochaired by NIDA International Program’s leadership, Dr. Tom Clarke and Dr. Lindsey Friend. It was attended by over 200 individuals from 73 countries. The meeting included several plenary sessions, four breakout sessions, and an international research poster session featuring 90 posters presented by substance use and addiction researchers from 26 countries.
The Forum began on June 14 with two sessions on advancing quality of addiction study programs and on addiction neuroscience research in Bulgaria, as well as a workshop on how to get addiction research published in peer-reviewed journals.
Day 2 started with the official welcome and updates on NIDA’s programs. This was followed by four breakout sessions on addiction treatment and criminal justice systems, professional healthcare education regarding medical cannabis, addressing opioid stigma in pharmacies, and effective interventions to increase treatment access and intake in real-world settings across the globe. The meeting concluded with two plenary sessions that discussed substance use and associated health problems in humanitarian settings and addressed two current global topics, namely, emerging synthetic drugs in Latin America and the Caribbean and the treatment of children with substance use problems. Rounding out the program were a joint workshop conducted by NIDA staff and staff from the CPDD, as well as a poster session.
Following are brief summaries of the topic sessions presented at this year’s International Forum.
Dr. Clarke provided a high-level overview of NIDA’s research priorities. In the United States, the most pressing problem continues to be the opioid overdose crisis, which is currently driven by co-use of fentanyl and stimulants and disproportionately affects American Indian/Alaska Native and Black communities. Also highly concerning are continued high rates of unintentional fentanyl-related overdose deaths in youths ages 15-19. In response, NIDA’s 2022 to 2026 strategic plan has identified five core research priorities, including (1) understanding drugs, the brain, and behavior; (2) prevention, treatment, and recovery; (3) the intersection of substance use and HIV; (4) implementation science; and (5) innovative heath applications.
Dr. Clarke also introduced several large programs that NIDA supports — partly together with other NIH Institutes — to address the opioid public health crisis. One of these efforts is the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative® — an NIH-wide effort to speed scientific solutions to the opioid health crisis that is jointly led by NIDA and the National Institute on Neurological Disorders and Stroke. Other major NIDA-supported research efforts include the longitudinal HEALthy Brain and Child Development (HBCD) and Adolescent Brain Cognitive Development (ABCD) studies, the HEALing Communities Study, the Justice Community Opioid Innovation Network (JCOIN), the Harm Reduction Research Network, and the NIDA Clinical Trials Network. Together, these efforts address challenges, such as emerging drugs (e.g., xylazine), increasing fentanyl and polysubstance use, persistent stigma, better care for hard-to-reach and underserved populations, continuity of care for substance use disorders (SUDs), and novel harm reduction approaches.
Dr. Friend summarized the activities of the NIDA International Program and its role in international policy development, information, exchange, research, and training. In particular, NIDA supports international research through grants awarded to U.S. researchers partnering with foreign investigators. NIDA’s international training and research programs include INVEST postdoctoral fellowships and Hubert H. Humphrey Fellowships. INVEST fellowships offer a 12-month postdoctoral research training with a NIDA grantee that includes professional development activities to establish personal relationships between the fellows and NIDA grantees and NIDA officials. They are for international researchers with a doctoral degree and a minimum of 2 years postdoctoral experience. Hubert H. Humphrey Fellowships are mid-career fellowships to approximately 12 individuals per year that include a 10-month research fellowship at Virginia Commonwealth University as well as 6-week professional affiliations, allowing fellows to make connections to advance their ongoing work. Additionally, NIDA offers the Distinguished International Scientist Collaboration Awards (DISCA) that fund innovative collaborations between international and NIDA-funded senior researchers. Dr. Friend also highlighted NIH’s Research Portfolio Online Reporting Tool, NIH RePORTER ( https://reporter.nih.gov ), as an excellent tool for learning about NIDA-funded projects or investigators funded in other countries.
This breakout session was chaired by Dr. Gregory Bunt from the International Society of Addiction Medicine (ISAM), who introduced the International Consortium for Alternatives to Incarceration (ICATI). ICATI works with countries, organizations, professionals, and program sites to support the global development of treatment, care, and accountability as alternatives to incarceration for individuals who use drugs and become involved with the justice system. At various stages in the judicial process, the justice system can divert people to treatment and services in the community instead of incarcerating them. This has been shown to reduce recidivism. To help adopt and implement such measures, ICATI promotes and supports all phases of national and regional planning, training, technical assistance, evaluation, and implementation; identifies, develops, and provides resources; and helps establish international networks.
In lieu of Dr. Carl Erik Fisher from Columbia University in New York, who was not able to attend the meeting, Dr. Bunt also gave Dr. Fisher’s presentation on the “Portuguese model” of decriminalization as an alternative harm reduction approach for treating SUDs in minoritized communities. Decriminalization means elimination of criminal penalties for drug possession for personal use; it differs from depenalization, which generally means that criminal penalties are reduced or not enforced but are not legally eliminated, and from legalization of drug use. This approach was first implemented in Portugal, where drug possession was decriminalized in 2001 but people carrying a personal drug supply had to get mandatory treatment. This was accompanied by several other socio-medical and harm-reduction interventions for a holistic approach with wrap-around services. However, because existing laws against personal drug use had already been only loosely enforced, decriminalization may ultimately have formalized existing practices rather than drive new norms and attitudes. In the United States, a similar approach has been implemented in Oregon but has been less successful because people were not diverted to effective treatment. This suggests that even the best reform programs do not guarantee success because drug-related problems are shaped by additional factors, such as cultural attitudes, social support networks, or mental health resources.
Dr. David Martell from the Canadian Society of Addiction Medicine reported on Canada’s drug decriminalization efforts. Canada has a history of targeted exemptions from penalizing drug use, from prescription maintenance programs and wide availability of opioid agonist therapy to supervised consumption sites and drug checking programs. Dr. Martell also listed various legislative approaches to drug decriminalization, such as the 2017 “Good Samaritan Drug Overdose Act” or cannabis legalization in 2018, which legalized personal use but maintained criminal penalties for certain offenses. This legalization resulted in increased cannabis use for most age groups and a temporary increase in the cannabis industry, but more Canadians now get cannabis legally. A newer decriminalization pilot program started in 2023 decriminalizes use of small amounts of opioids, crack, cocaine, methamphetamine, or MDMA at certain sites (e.g., private residences, but also overdose prevention, drug checking, or supervised consumption sites). The aim is to eliminate the harms associated with drug seizure, help connect people who use drugs to services and support, and enhance public awareness and understanding. However, over the first 12 months, the project has not yielded benefits, and many issues are also still unaddressed. Dr. Martell concluded that Canada’s national drug policy landscape is still fragmented and the search for the best approach continues.
Dr. Hamed Ekhtiari from the University of Minnesota and ISAM Regional Council chair, discussed how the ISAM Global Expert Network (ISAM GEN) can contribute to global drug policy reforms. ISAM’s organizational hierarchy allows for representation and policy involvement across the globe through regional representatives, national ambassadors, addiction medicine societies, and 10 country experts for each country who represent the ISAM GEN. By eliciting information from these experts and conducting a range of global surveys, ISAM GEN can help map and reshape global policies. ISAM GEN has established a well-honed road map for conducting their surveys, from idea development and steering committee formation all the way to manuscript submission. ISAM GEN’s first global survey assessed treatment service provision for opioid use disorder by querying national addiction societies and organizations in 39 countries from six continents. It gathered valuable information on availability of different types of opioids and availability of different types of treatment services for opioid use disorder, harm reduction facilities, and 12-step programs. Researchers interested in establishing their own international working groups or developing surveys can contact ISAM for further information.
In this breakout session, which was moderated by Dr. Richard Isralowitz from the Ben-Gurion University of the Negev—RADAR Center in Israel, Dr. Richard Rawson, professor emeritus from the University of California, Los Angeles, first provided a historical overview of substance use training in professional curricula. He noted that information on substance use and its impact has only recently been integrated into professional healthcare training rather than being covered only in ad-hoc separate training events. Since 2000, training in substance use and its treatment has become more formalized, with exams and certification processes offered by national and international certification organizations. International training activities are coordinated by the International Consortium of Universities for Drug Demand Reduction (ICUDDR), which facilitates networking among universities to promote high-quality education and training for prevention, treatment, and public health intervention purposes. As a result, many universities now integrate alcohol, tobacco, and other drug content into their curricula, often within many specialty areas; however, cannabis and medical marijuana remain a new curriculum topic.
Dr. Yuval Zolotov from the Albert Einstein College of Medicine in the Bronx, New York, summarized the results of an international survey among healthcare professions’ students in Israel, Malta, Greece, Cyprus, Russia, Belarus, Thailand, and the United States regarding their attitudes, beliefs, and knowledge about medical cannabis. Participants were 4,427 students (70% female) of medicine, nursing, social work, and psychology; 74% came from countries where medical cannabis was legal. Dr. Zolotov reported that, overall, respondents expressed relatively high levels of support for medical cannabis, but also concerns about potential risks and harms. Almost all respondents believed that medical cannabis should be included in their education and practical experiences, but almost 87% reported receiving no formal education in this area. As a result, about 70% of respondents felt unprepared to answer patient questions about medical cannabis. Dr. Zolotov concluded that a great need for formal education in medical cannabis exists and that standardized curricula can help bridge the existing gaps.
Dr. Mazen Sakka from the Substance Abuse Research Center, Palestine, summarized a similar survey among medical staff at two hospitals and students at four universities in the Palestinian territories (West Bank, Gaza Strip) about their knowledge, beliefs, and attitudes regarding medical cannabis. The survey also explored the roles of gender, religiosity, and legal status of medical cannabis on these domains. In the Palestinian territories, cannabis is considered a schedule I substance, together with other addictive drugs. The survey found that while most medical staff and many students believed that medical cannabis can help certain patients, they also saw a high risk of mental and physical health problems. However, many respondents had only limited knowledge on the subject. Additionally, attitudes and beliefs differed somewhat between males and females and were affected by religious views and the fact that cannabis is considered an illegal drug. Nevertheless, Dr. Sakka noted that most respondents seemed open to more information or training on medical marijuana, supporting efforts to enhance such activities.
Given the apparent need for and interest in professional healthcare education on medical cannabis, Dr. Mikhail Kogan from George Washington University and Dr. Leslie Mendoza Temple from the University of Chicago described a Delphi process to identify teaching standards and essential medical cannabis education competencies. The Drug Enforcement Agency in the United States is set to reschedule cannabis to a lower status, which would require all pharmacies in the United States to carry cannabis products. After a 2021 scoping review found that healthcare trainees lack proper education and knowledge about medical cannabis, implementation of expanded competencies-based curricula is essential. Drs. Kogan and Temple described the Delphi process methodology, which relies on synthesizing opinions among a group of experts via repeated rounds of discussion until a consensus is reached. In this case, the process involved 23 experts with different areas of expertise, who identified six core competencies to guide development of medical school curricula in the United States and Canada. These included (1) understanding the basics of the endocannabinoid system, (2) describing the main components of the cannabis plant and their effects, (3) reviewing the legal and regulatory landscape on cannabis in the United States, (4) describing the evidence base for health conditions that are commonly managed with cannabis, (5) understanding the potential risks of medical cannabis use, and (6) understanding basic clinical management with medical cannabis.
This breakout session with Dr. Beth Sproule and Dr. Braiden Cutmore from the Canadian Centre for Addiction and Mental Health and Dr. Sarah Bhatti from the Public Health Agency of Canada (PHAC) centered on the stigma that people who use drugs and people with chronic pain frequently face. The session focused specifically on stigma from pharmacy professionals. As Dr. Bhatti noted, experiences of stigma may decrease use of treatment and social services as well as quality of care. A 2019 report by the Canadian Chief Public Health Officer concluded that responding to stigma in the health system requires a comprehensive approach through education, training, practice, and policy. PHAC conducted a literature review to clarify the nature and manifestations of stigma; assess stigma related to treatment with naloxone, opioid agonist therapy, harm reduction approaches, and opioid treatment for pain in pharmacy professionals; as well as anti-stigma approaches. The review identified several key ingredients for anti-stigma programs, such as repeated social contact, demonstration of recovery, myth busting, and enthusiastic facilitation. Dr. Bhatti also indicated that targeted education is more successful than general education.
Dr. Cutmore described several stakeholder roundtables organized by PHAC that discussed definitions of stigma, experiences of stigma, positive experiences with pharmacies, and potential messages for pharmacy professionals. The roundtables included people with opioid use disorder, people with chronic pain, and pharmacy professionals, respectively. Based on the feedback from the three stakeholder groups, six messages for pharmacists were drafted that addressed the main themes raised — for example, that pharmacy professionals need to see patients as a whole person and treat them with dignity and respect, that they need to understand the patient’s opioid medication experience and act as allies to support patients, or that they need to proactively engage and empower patients through education. Agreement with these messages was then assessed in an anonymous survey among roundtable participants. According to Dr. Cutmore, the roundtables and resulting messages highlighted that it is crucial for pharmacy professionals to challenge negative attitudes and beliefs by reflecting on their assumptions toward people taking opioids and recognize their impact. Additionally, they need to help empower through communication their patients who are prescribed opioids.
Dr. Sproule then presented a newly developed tool kit delineating strategies for pharmacy professionals to address opioid stigma in pharmacies. It highlights eight key strategies to support people who use opioids, such as respecting all customers equally, getting to know customers, offering support through education, explaining and reviewing pharmacy process, providing harm reduction services, delivering compassionate healthcare, respecting the right to privacy, and raising public awareness. The toolkit also provides tips on how to put those strategies into practice. One concept Dr. Sproule highlighted is the idea that “words matter” — that how one talks to or about people who use substances can either reinforce or, in contrast, counter stigmatizing attitudes, views, and actions. The toolkit also includes social media assets and posters to raise awareness of and address opioid stigma in pharmacies. Infographics, videos, courses, and other resources are also available. The toolkit was launched in February 2024 with a webinar attended by more than 250 pharmacy professionals and other stakeholders.
This breakout session was chaired by Dr. Adrian Abagiu from the Romanian National Institute for Infectious Diseases and Dr. Matei Bals from the ARENA OST Center in Romania. Dr. Abagiu reported on a program in Romania to increase adherence to antiretroviral therapy (ART) among people living with HIV (PLWH) who were incarcerated. He described that some of these individuals refused ART due to restrictions according to detention regulations. To improve ART adherence, they developed an information program involving a 20-minute PowerPoint presentation, a 10-minute Q&A session, and information leaflets for small groups of PLWH at one of the prisons. The intervention improved adherence, but the effect declined after 4 months. As a result, the program was refined further and assessed in a study comparing 100 PLWH who received the intervention with 50 PLWH who did not in one jail. Before the intervention, ART refusal rates were the same in both groups. After the intervention, refusal rates declined in the intervention group, but remained relatively stable in the control group; again, the effect was lost at 4 months after the intervention. Based on these findings, the intervention was delivered every 2 months to all new PLWH arriving at the prison, and while it had to be halted during the COVID-19 pandemic, it was resumed after the end of the pandemic.
Next, Dr. Dace Svikis from Virginia Commonwealth University described the Expanding Medical Prevention and Outreach While Enhancing Recovery and Retention (EMPOWER) project that seeks to increase engagement and retention in SUD and HIV treatment for underserved Black people in Baltimore, Maryland. Dr. Svikis explained that Baltimore has one of the highest rates of new HIV cases and also has the highest fatal overdose rates among large cities in the United States, but is also a leader in SUD treatment and harm reduction approaches. EMPOWER was assessed within the Recovery Enhanced by Access to Comprehensive Healthcare (REACH) Health Services Program that offers comprehensive outpatient SUD treatment as well as mental health counseling. However, Black individuals in the program were less likely to engage in SUD treatment, more likely to drop out of care, and thus less access to HIV-related testing and care. The EMPOWER program seeks to address these disparities using tailored, patient-focused, evidence-based interventions to engage and retain Black individuals in treatment. Importantly, the EMPOWER team includes people who have lived experience and represent the population of focus, such as peer recovery specialists and nurse care managers. EMPOWER uses evidence-based interventions, such as motivational interviewing, continency management, safer sex skill building, and Seeking Safety, a cognitive behavioral therapy for post-traumatic stress disorder and SUD. The EMPOWER program started recruitment in February 2024 and will last 6 months, after which regular REACH services will continue. Preliminary findings indicate that EMPOWER can increase treatment retention at 3 months compared with the normal REACH program; additional data will be gathered in the coming months.
The third presenter was current Hubert H. Humphrey Fellow Thinzar Tun from Myanmar, director of the Asian Harm Reduction Network (AHRN) and Best Shelter Myanmar, who reported on a program she is spearheading to increase treatment access and intake for people who use drugs (PWUD) or inject drugs (PWID). She explained that Myanmar has about 93,000 PWID, about 35% of whom have HIV. AHRN provides facility-based harm reduction, treatment, and care, whereas Best Shelter offers community-based harm reduction, prevention, referral, and care. Specific services include outreach, health education, self-help groups, job creation efforts, peer education, counseling, and treatment. Some services are specifically aimed at women as a particularly vulnerable population, such as services to improve sexual and reproductive health, as well as pre- and postnatal care, and services to curb gender-based violence. Ms. Tun specifically described their needle and syringe programs, including efforts to return and safely dispose of used needles and syringes, as well as HIV testing and treatment. These are implemented either during outreach with mobile units or at fixed locations in clinics or in the community. Ms. Thun reported that for 2022, about 18 million needles and syringes were distributed, with a return rate of 86%. For HIV testing, the program brought testing closer to the PWID and their families, allowed for effective linkage to care and rapid ART initiation, as well as testing and treatment in hard-to-reach locations. The program reduced the proportion of PWID who were HIV positive and achieved high linkage to treatment and ART initiation for both PWUD and PWID and their sexual partners. Ms. Tun concluded that to address drug use and HIV in countries such as Myanmar, understanding the context and needs of clients is essential, and that community inclusion and harm reduction approaches work.
This plenary session was started by Dr. Anja Busse from the United Nations Office on Drugs and Crime (UNODC), who provided an update on addressing substance use in humanitarian emergencies. Dr. Busse explained that humanitarian emergencies (e.g., disasters, armed conflicts, epidemics) threaten the lives and well-being of very large numbers of people or a very large percentage of a population, often result in displacement, and require assistance from multiple sectors. There is only limited evidence on substance use among displaced persons; however, there seem to be regional differences regarding the most commonly used substances. Displaced populations or people in humanitarian emergencies may face particular challenges related to drug use, such as sudden interruptions of patterns of drug use, disruption of treatment services, and resumption of drug use with increased risk of overdose; these compound social and mental health problems associated with humanitarian crises. Dr. Busse noted that substance use is included in humanitarian health guidance as part of mental health interventions. A Desk Review by the United Nations High Commissioner for Refugees (UNHCR) found that community-based, peer-led programs and training of healthcare workers in SUD treatment are feasible in low-resource and refugee settings and that brief interventions have significant potential. Opioid agonist therapy may also be possible in humanitarian settings with support from international donors and organizations. Several international policy documents have provided policy direction for addressing SUDs in humanitarian emergencies. UNODC and the World Health Organization (WHO) have a joint program for such situations, and the UNODC/WHO International Standards for Treatment of Drug Use Disorders can be adapted for humanitarian emergencies. A handbook by UNODC, UNHCR, and WHO will soon be published, disseminated, and field-tested. It creates an implementation framework for both the acute phase and the protracted phase of the emergency. It has identified two main principles — saving lives first (i.e., addressing life-threatening concerns such as overdose and withdrawal first), and full inclusion of people with SUD in other support available.
Dr. Dzmitry Krupchanka from the WHO described the organization’s approach to addressing substance use during humanitarian emergency responses. He noted that people in humanitarian settings have much higher rates of mental health problems than other populations; moreover, mental and physical health conditions are often comorbid with SUDs. Dr. Krupchanka mentioned a 2024 WHO draft resolution on strengthening mental health and psychosocial support (MHPSS) before, during, and after humanitarian emergencies. The resolution includes MHPSS as an integral component of preparedness, response, and recovery activities in all emergencies. He then reviewed the Inter-Agency Standing Committee (IASC) Guidelines on Mental Health and Psychosocial Support in Emergency Settings, which delineate key actions to minimize harm related to alcohol and other substance use. These measures aim to conduct rapid assessments, prevent harmful alcohol and other substance use and dependence, facilitate harm reduction interventions in the community, and manage withdrawal and other acute problems. An open, free course is available to learn about this, as well as some cultural adaptations. Additionally, several WHO resources to address substance use and its consequences in humanitarian settings will be forthcoming.
Dr. Karen Paul from the IASC Reference Group for Mental Health and Psychosocial Support in Emergencies talked about interagency collaboration regarding substance use and SUD in humanitarian emergencies. She emphasized that a multi-sector response is needed in such situations, and some of these sectors are also addressed in the IASC Guidelines mentioned by Dr. Krupchanka. Dr. Paul also described the IASC MHPSS Reference Group, which is cochaired by WHO, UNODC, and UNHCR and involves over 11 member agencies as well as five observers. Their current priority is developing materials for training and orienting various groups of humanitarian workers on substance use, from materials for basic communication to materials on advanced interventions. For example, orientation materials are being developed on SUDs as health conditions, how to provide support, life-threatening conditions related to substance use, and similar topics. These materials are currently being field tested, with an eye to adapting them to various cultures and contexts. A substance use module for integrating MHPSS into disaster risk management and preparedness training is also being developed, including a framework for assessment and action.
Finally, Dr. Mustafa al’Absi from the Duluth Global Health Research Institute and the University of Minnesota discussed the implications of traumatic stress and substance use in the context of humanitarian emergencies. He noted that trauma exposure, particularly in children and adolescents, is associated with an increased risk for SUD; moreover, substance use can impact the course and severity of traumatic stress symptoms. Increases in political conflicts as well as natural disasters have led to rising mental health and substance use problems. Consequently, it is important to integrate mental health and substance use services in emergency responses and increase capacity for trauma-informed care among humanitarian workers. Dr. al’Absi presented case studies from recent conflicts and natural disasters, such as the conflicts in Syria, Yemen, and Afghanistan, or the an earthquake in Turkey. Each of these has unique features regarding substance use that need to be considered. The crisis in Afghanistan also provided an example of partnerships between WHO, UNODC, and others for treatment of SUDs to improve the health and well-being of vulnerable populations. Dr. al’Absi concluded that guidelines informed by epidemiological, intervention, and implementation knowledge are needed to address the challenge of SUD in humanitarian settings. He also issued a call to action for improving substance use services capacity and integration in humanitarian emergencies in order to help prioritize the well-being of affected populations in emergency response efforts. These efforts also must address the issue of stigma in order to be effective.
In this session moderated by Dr. Andrew Thompson from the Bureau of International Narcotics and Law Enforcement Affairs (INL), Dr. Marya Hynes from the Inter-American Observatory on Drugs reported on emerging synthetics and new psychoactive substances (NPS) in Latin America and the Caribbean. She noted that synthetic drugs have proliferated in those drug markets, particularly since 2013, and that NPS also have become more common. Of concern are amphetamine-type stimulants (ATS), such as amphetamines and prescription stimulants, methamphetamine, synthetic hallucinogens, and synthetic opioids. Information on NPS is coming from drug seizures and early warning data that are reported to the Early Warning System for the Americas. These notifications have highlighted several trends, such as appearance of “pink cocaine” (a mixture of various synthetic compounds); increasing prevalence of benzodiazepines in females in every population studied; greater presence of stimulants, particularly among females; synthetic cannabinoids; and a variety of synthetics sold as other drugs. As Dr. Hynes emphasized, even at low prevalences, these trends are concerning because they indicate that people are using more and more mixed and adulterated substances that have unknown composition, unknown effects, often high potency, and often rapid onset and long duration of effects. The most severe implications are for countries with fragile health care systems. These developments affect particularly teenagers and young adults, including health risks and mental health issues that drive drug use and are themselves driven by drug use. These developments need to inform efforts for detection, treatment, and prevention.
Dr. Antonio Pascale from the University of Montevideo further described the health impacts of NPS and increasing availability of adulterated drugs among younger users. For example, adulterants may potentiate the toxicity of the original drugs or induce unintended toxic effects. ATS are associated with harmful effects, such as hyperthermia, which can be exacerbated by the settings where these drugs are often consumed (e.g., clubs with high temperatures, poor ventilation, and intense physical activity); serotonergic syndrome; and hyponatremia. Synthetic cannabinoids, which are increasingly used by young people as well as other vulnerable populations, can be associated with acute toxicity as well as greater morbidity and mortality in the context of polydrug use. Synthetic opioids (e.g., fentanyl and its analogues, nitazenes) are an increasing problem in Latin America with the associated acute toxicity and risk of fatal overdoses. An emerging concern is illicit use of benzodiazepines (often as adulterants of other drugs), which is associated with acute intoxication and altered consciousness that increases vulnerability to sexual crimes and other harms. Dr. Pascale concluded that to address this public health problem effectively, it is essential to strengthen networks involving government agencies, clinical and forensic laboratories, universities, toxicology centers, and nongovernment agencies with access to PWUD.
Dr. Hendrée Jones from the University of North Carolina at Chapel Hill provided an overview of the Child Intervention for Living Drug-free (CHILD) program to treat children under age 12 for substance use problems. Dr. Jones explained that children are increasingly victims of drug trafficking and drug use within their families and communities, leading to children as young as 5-12 years having an SUD. The CHILD intervention was developed to respond to this growing threat. It is a global, evidence-based program with an integrated health approach, full spectrum of services, and family involvement. It includes professional development and a tailored program for each country that uses techniques (e.g., motivational interviewing, mindfulness, dialectic behavior therapy, art therapy) that can be translated into language and activities appealing to children. The program has been disseminated to numerous countries through “training of trainers,” webinars, and “Echo” training. Dr. Jones also shared information on a randomized clinical trial of the CHILD intervention in children ages 7-12 in India. Preliminary results indicate that it reduces substance use in these children at 12 months after treatment better than usual care.
In this session chaired by Dr. Carly Searcy from ICUDDR, Mr. Jordan Turner, also from ICUDDR, provided an overview of the current state of quality assurance in specialty addiction studies programs. He shared results from a survey of 322 ICUDDR members that assessed program quality along six dimensions of care in members’ curricula. Among the 88 respondents, 63% addressed quality improvement through their curriculum plans. However, qualitative data indicated a minimal focus on quality of care among institutions; barriers within member institutions that prevented quality of care to be addressed, and a need for ICUDDR’s assistance in curriculum building. Mr. Turner concluded that the study positioned ICUDDR to work with members to create frameworks for addressing quality and quality improvement.
Dr. Amelie Lososová from the Charles University in Prague presented previous research on establishing quality assurance at the university level. Several organizations, such as the Substance Abuse and Mental Health Services Administration, American Society of Addiction Medicine, and American Psychiatric Association in the United States, as well as the WHO have addressed quality standards in education programs. Similarly, two projects (WAVE project and FENIQS-EU project) have been conducted in Europe, and for the WAVE project, several project papers will be published soon. Dr. Lososová noted the importance of making education a research focus and highlighted several future research questions and challenges—for example, whether international standards are really needed, what areas of addiction research should be included; which educational programs should apply the standards; and how regional, cultural, and communication differences can be accommodated.
Dr. Dennis McCarty from the Oregon Health & Science University discussed what kind of research is needed. Examples included integration of research into educational standard development, integration of outcome measures into training processes and systems of care, assessments of the impact of standards on care delivery and outcomes, and cross-national comparisons of training and training standards. Dr. McCarty pointed out that each country is unique, and it is therefore important to determine which facets of addiction studies programs are replicable and generalizable. The relatively new areas of dissemination and implementation research are also crucial to determine how research findings can be translated into standards of practice on an international scale.
In the final presentation, Dr. Victor Capoccia from the Technical Assistance Collaborative discussed the development a certification framework for addiction studies programs as a documentation of program quality. He also highlighted questions that would need to be addressed in this process. For example, what should be included in a certification according to international standards (e.g., minimum content for the curriculum, minimum hours of exposure to content, number and qualifications of faculty). Equally important is an understanding of factors that drive differences in standards across the globe. Levels of education and credentialing desired (e.g., nondegree certification, associate, baccalaureate, master’s), cultural and historical contexts of drug use, governmental/legal context, health system infrastructure, and medical traditions all need to be considered. In fact, one set of standards may not be appropriate for all international scenarios. Thus, development of any certification or accreditation process must first determine what components are nonnegotiable and must be uniform and what country or regional characteristics might be accommodated in variations from the standards.
This session presented the results of three sets of studies conducted by a large multinational team of researchers in Bulgaria over the past 20 years. As the first presenter, Dr. Jasmin Vassileva from Virginia Commonwealth University, explained, Bulgaria is well suited for their studies of people who use opiates and stimulants because it is located on one of the main heroin trafficking routes into Europe and is a major center for amphetamine production. Dr. Vassileva is investigating which dimensions of impulsivity are associated with addiction in general or specific drug classes. Her team used computational approaches to address this question, including data-driven, machine learning processes for classification and prediction, as well as theory-driven cognitive modeling to increase precision of neurocognitive phenotyping. Dr. Vassileva presented results of several of their studies that have been published in recent years. The findings indicated that some dimensions of impulsivity are common across addictions, whereas others are unique to specific drug classes. The studies also demonstrated that computational approaches have significant potential as phenotyping tools, for identifying markers for addictions, for increasing precision of neurocognitive assessments, and for prognosis and diagnosis. They may also help refine neurocognitive phenotypes and identify different biotypes of addictions with different underlying mechanisms, which may have implications for prevention and intervention.
Dr. Elena Psederska from the New Bulgarian University presented on studies assessing the interplay of personality and neurocognitive function in stimulant and opioid use disorders. Specifically, the team studied the effects of psychopathy on neurocognitive domains of impulsivity in people who previously had used heroin and amphetamine. They assessed the effects of the interpersonal/affective domain and the impulsive/antisocial domain of psychopathy on impulsive choice and impulsive action in both groups. The analyses identified an interaction between the two dimensions of psychopathy and dependence on specific classes of drugs. Some profiles were common across SUDs, whereas others were unique for specific drugs. Another investigation assessed neurocognitive impulsivity in people who used heroin at different times of abstinence. These analyses demonstrated that while some deficits in impulsive choice and impulsive action may only occur in early abstinence, others may persist even with sustained periods of abstinence. Overall, Dr. Psederska concluded that personality influences both common and unique profiles of impairments in neurocognitive impulsivity in people who use opioids or stimulants, and that these impairments may persist even with sustained abstinence. Thus, extended treatment and rehabilitation approaches that are tailored to individual personality profiles are needed.
The final presentation by Dr. James Bjork from Virginia Commonwealth University addressed similarities and differences in brain recruitment by reward, inhibition, and memory in people with different SUDs. The study included individuals with opioid, stimulant, or polysubstance use disorder as well as controls and compared individual differences in brain activation as measured by MRI while participants were conducting three different tasks. The study is still ongoing, but there is preliminary evidence that brain areas activated by specific tasks can be correlated with characteristics determined in addictions neuroclinical assessments, such as emotion-related impulsivity, cognitive difficulties in daily life, or inattention.
In this workshop, Adam Gordon and Casy Calver from the International Society of Addiction Journal Editors (ISAJE) highlighted three essential aspects to publishing addiction research: choosing a journal, submission and peer review, and authorship. They noted that there are over 100 peer-reviewed addiction journals, and journals from other disciplines also publish addiction articles. They listed 15 factors to consider when choosing a journal as well as questions to ask of a journal (e.g., whether it reaches the specific audience authors want to target, the journal’s mission and content area). Practical aspects, such as editorial support provided or cost of publication/open access, are also important, as are various metrics associated with the journal. These include journal metrics (e.g., impact factor), public impact metrics (e.g., Altmetric attention score), editorial efficiency metrics (e.g., time to first decision, acceptance rate), and author metrics.
For submitting manuscripts, authors first need to check author guidelines, select an appropriate article type, and obtain approval from all authors to submit. Once a manuscript is submitted, a multistep peer-review process follows that may include one or more author revision steps. Peer review is essential to advise the editorial decision-making process, justify rejections, improve the quality of acceptable manuscripts, and identify instances of ethical or scientific misconduct. While the reviewers make recommendations, the editors make the final decision and may even disagree with reviewer recommendations. If the decision is to revise and resubmit the paper, authors should decide if they want to resubmit the paper and, if so, respond to each criticism by either modifying the manuscript or debating/refuting the criticism.
The issue of authorship is increasingly important. The authors on a manuscript certify a public responsibility for the truth of the publication. Authorship also is an indicator of productivity, promotion, and prestige, and credit should be assigned equitably. Especially in addiction research, inclusion of people with lived experience (e.g., patient coauthors in case studies) is important but authors also need to be aware of and sensitive to ethical considerations. Several measures can be taken to avoid authorship problems (e.g., early agreement on the precise roles of all contributors; periodic review of authorship credit status, and adherence to authorship guidelines). Overall, authors must avoid the “seven deadly sins” of carelessness, redundant publication, unfair authorship, undeclared conflict of interest, human subjects’ violations, plagiarism, and other fraud. To avoid plagiarism, all sources must be appropriately acknowledged and permission for use of large amounts of others’ written or illustrative materials obtained. This also applies to self-plagiarism, as authors are not allowed to reuse previously published materials when rights have been assigned to the publisher. The ISAJE provides author resources on their website ( https://www.isaje.net/ ); additional information is available in the JAMA Users’ Guide to Medical Literature and from the Committee on Publication Ethics (COPE) ( https://publicationethics.org ).
Accessibility Links
The American Astronomical Society (AAS) , established in 1899 and based in Washington, DC, is the major organization of professional astronomers in North America. Its membership of about 7,000 individuals also includes physicists, mathematicians, geologists, engineers, and others whose research and educational interests lie within the broad spectrum of subjects comprising contemporary astronomy. The mission of the AAS is to enhance and share humanity's scientific understanding of the universe.
The Institute of Physics (IOP) is a leading scientific society promoting physics and bringing physicists together for the benefit of all. It has a worldwide membership of around 50 000 comprising physicists from all sectors, as well as those with an interest in physics. It works to advance physics research, application and education; and engages with policy makers and the public to develop awareness and understanding of physics. Its publishing company, IOP Publishing, is a world leader in professional scientific communications.
A publishing partnership
Anna Trindade Falcão 1 , T. J. Turner 2 , S. B. Kraemer 3 , J. Reeves 3,4 , V. Braito 3,4,5 , H. R. Schmitt 6 , and L. Feuillet 3
Published 2024 September 9 • © 2024. The Author(s). Published by the American Astronomical Society. The Astrophysical Journal , Volume 972 , Number 2 Citation Anna Trindade Falcão et al 2024 ApJ 972 185 DOI 10.3847/1538-4357/ad6b91
You need an eReader or compatible software to experience the benefits of the ePub3 file format .
1638 Total downloads
Author affiliations.
1 Harvard-Smithsonian Center for Astrophysics, 60 Garden St., Cambridge, MA 02138, USA
2 Eureka Scientific, Inc., 2452 Delmer St., Suite 100, Oakland, CA 94602, USA
3 Institute for Astrophysics and Computational Sciences, The Catholic University of America, Washington, DC 20064, USA
4 INAF—Osservatorio Astronomico di Brera, Via Bianchi 46, 23807, Merate (LC), Italy
5 Dipartimento di Fisica, Università di Trento, Via Sommarive 14, Trento 38123, Italy
6 Naval Research Laboratory, Washington, DC 20375, USA
Anna Trindade Falcão https://orcid.org/0000-0001-8112-3464
T. J. Turner https://orcid.org/0000-0003-2971-1722
S. B. Kraemer https://orcid.org/0000-0003-4073-8977
J. Reeves https://orcid.org/0000-0003-3221-6765
V. Braito https://orcid.org/0000-0002-2629-4989
H. R. Schmitt https://orcid.org/0000-0003-2450-3246
L. Feuillet https://orcid.org/0000-0002-5718-2402
AGN host galaxies ; Seyfert galaxies ; High energy astrophysics
Receive alerts on all new research papers in American Astronomical Society ( A A S ) journals as soon as they are published. Select your desired journals and corridors below. You will need to select a minimum of one corridor.
Please note, The Planetary Science Journal (PSJ) does not currently use the corridors.
What are corridors? opens in new tab
We report the serendipitous multiwavelength discovery of a candidate dual black hole system with a separation of ∼100 pc, in the gas-rich luminous infrared galaxy MCG-03-34-64 ( z = 0.016). Hubble Space Telescope/Advanced Camera for Surveys observations show three distinct optical centroids in the [O iii ] narrow-band and F814W images. Subsequent analysis of Chandra/ACIS data shows two spatially resolved peaks of equal intensity in the neutral Fe K α (6.2–6.6 keV) band, while high-resolution radio continuum observations with the Very Large Array at 8.46 GHz (3.6 cm band) show two spatially coincident radio peaks. Fast shocks as the ionizing source seem unlikely, given the energies required for the production of Fe K α . If confirmed, the separation of ∼100 pc would represent the closest dual active galactic nuclei reported to date with spatially resolved, multiwavelength observations.
Export citation and abstract BibTeX RIS
Original content from this work may be used under the terms of the Creative Commons Attribution 4.0 licence . Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
The masses of supermassive black holes (SMBHs) in active galactic nuclei (AGNs) correlate with the global properties of their host galaxies' stellar components, such as luminosity, mass, and velocity dispersion, extending over kiloparsec scales (e.g., Kormendy & Ho 2013 ). This correlation highlights the need to understand the mechanisms driving SMBH growth.
Both galactic evolutionary models and observations suggest that a significant fraction of AGNs, particularly those at the center of large-scale structures, undergo major mergers (e.g., De Lucia & Blaizot 2007 ; Hopkins et al. 2008 ; Ginolfi et al. 2017 ; Castignani et al. 2020 ). Hydrodynamical simulations further demonstrate that major mergers induce gas inflows toward galactic centers, potentially triggering both star formation and accretion onto central SMBHs (Mayer et al. 2007 ). However, the overall impact of these events on SMBH growth throughout cosmic time remains poorly constrained.
SMBH pairs, often manifested as dual AGNs, provide distinctive evidence for merger-fueled SMBH growth (e.g., Wassenhove et al. 2012 ). Numerous dual AGN candidates have been identified using various techniques, including optical spectroscopy with emission line ratios (e.g., Liu et al. 2011 ), hard X-ray emission (e.g., Koss et al. 2011 ), and double-peaked narrow emission lines (e.g., Smith et al. 2010 ; Koss et al. 2023 ). Nonetheless, these methods have limitations, and multiwavelength follow-up observations have revealed a substantial number of false positives (e.g., Fu et al. 2011b ).
The advent of gravitational-wave astronomy, with the potential for detection through pulsar timing arrays (e.g., Verbiest et al. 2016 ), has heightened the importance of understanding the formation timescales of binary systems. Studying kiloparsec and subkiloparsec dual AGNs offers a unique window into the final stages of SMBH binary coalescence, a crucial process in gravitational wave astronomy.
Dual AGNs separated by kiloparsec or subkiloparsec scales are inherently more challenging to detect and investigate than wider-separation systems (e.g., >3 kpc). This difficulty arises from increased obscuration in late-stage mergers (e.g., Koss et al. 2016 ; Ricci et al. 2021 ; De Rosa et al. 2022 ), limitations in telescope spatial resolution (particularly at subkiloparsec scales), the scarcity of detected radio-bright dual systems (Burke-Spolaor 2011 ), and the limitations of optical selection using double-peaked narrow emission lines (prone to false positives; see Fu et al. 2011a ). Existing observations of dual AGNs tentatively suggest that AGN triggering becomes more prevalent in advanced mergers with stellar bulge separations <10 kpc (e.g., Koss et al. 2010 ; Fu et al. 2018 ; Stemo et al. 2021 ), aligning with simulations of SMBH accretion and evolution in such mergers (e.g., Blecha et al. 2018 ). Therefore, studying nearby galaxies hosting dual AGNs separated at subkiloparsec scales is crucial for advancing our understanding of the late stages of galaxy mergers, the triggering and fueling of AGN activity, and the dynamics of SMBH pairs (Steinborn et al. 2016 ). These close-separation systems provide a unique window into the processes leading to the eventual coalescence of SMBHs, which is a major source of gravitational waves, and plays a fundamental role in the growth of SMBHs and their host galaxies (Dotti et al. 2012 ; Kharb et al. 2017 ).
While several dual AGN candidates have been proposed at scales of hundreds of parsecs, often supported by single-wave band observations, these have frequently been challenged by subsequent studies. Notable examples include the nearby Seyfert NGC 3393 (Fabbiano et al. 2011 ), SDSS J101022.95 + 141300.9 (Goulding et al. 2019 ), and a third active nucleus in NGC 6240 (Kollatschny et al. 2020 ), later disputed in other works (Koss et al. 2015 ; Veres et al. 2021 ; Treister et al. 2020 ).
In this study, we present the serendipitous discovery of a candidate dual AGN system in MCG-03-34-64 (IRAS 13197-1627), a nearby early-type infrared luminous galaxy at z = 0.01654 (∼78 Mpc, from NASA/IPAC Extragalactic Database). 7 This galaxy is identified as one of the hardest X-ray sources in the local Universe (Tatum et al. 2016 ). Earlier X-ray observations with ASCA, XMM-Newton, and BeppoSAX (Dadina & Cappi 2004 ; Miniutti et al. 2007 ) revealed an extremely hard and complex source spectrum, attributed to heavy absorption from a multilayered and clumpy medium. MCG-03-34-64 also shows extended radio emission (∼300 pc), roughly aligned with the major axis of the host galaxy (Schmitt et al. 2001 ), and ∼2'' extent in mid-infrared aligned in the same direction as the radio structure (Hönig et al. 2010 ).
We have obtained Hubble Space Telescope/Advanced Camera for Surveys (ACS) imaging of MCG-03-34-64 in 2022 June (P.I.: Turner, proposal ID: 16847), and 50 ks of Chandra/ACIS-S observations in 2023 April (obs ids 25253, 27802, and 27803, P.I.: Turner). This paper presents the results of the analysis of these new data sets, combined with existing Very Large Array (VLA) radio, and Hubble Space Telescope (HST) optical imaging of the source. Throughout this paper, we adopt Ω m = 0.3, Ω Λ = 0.7, and H 0 = 70 km s −1 Mpc −1 , and a scale of 340 pc arcsec −1 , based on the redshift at the galaxy's distance.
Table 1 lists all observations used in this paper, including instruments, filters, observation dates, obs ids, and exposure times. Details on the reduction of new HST/ACS and Chandra/ACIS-S observations are provided in Sections 2.1 and 2.2 , respectively. For reduction and analysis of archival HST F814W, VLA 8.46 GHz imaging, and Suzaku and XMM-Newton spectroscopy, see Section 2.3 . All the HST data used in this paper can be found in MAST at doi: 10.17909/53rj-fw34 .
Table 1. Multiwavelength Observations of MCG-03-34-64
Wavelength | Instrument/ | Date | Observation | Exposure |
---|---|---|---|---|
Band | Filter | of Observation | ID | Time (s) |
Optical | HST/ACS FR505N | 2022-06-30 | jequ01020 | 1.5 10 |
HST/ACS FR647M | 2022-06-30 | jequ01010 | 2.0 10 | |
HST/ACS F814W | 2019-01-18 | jdrw9z010 | 7.0 10 | |
Radio | VLA/A (8.46 GHz) | 1995-07-15 | AK394 | 9.0 10 |
X-rays | Chandra/ACIS-S | 2023-04-19 | 25253 | 1.5 10 |
Chandra/ACIS-S | 2023-04-20 | 27802 | 1.8 10 | |
Chandra/ACIS-S | 2023-04-21 | 27803 | 1.7 10 | |
NuSTAR | 2009-07-01 | 60101020002 | 7.8 10 | |
XMM-Newton/Epic-pn | 2016-01-17 | 0763220201 | 1.0 10 |
Download table as: ASCII Typeset image
HST/ACS observations of MCG-03-34-64 were obtained using the linear ramp filter FR505N (narrow-band [O iii ]) centered at 5089.6 Å, to characterize the morphology of the emission-line gas, while a continuum medium band image was obtained using FR647M, centered at 5590 Å. These filters have bandwidths of 2% and 9%, respectively. Standard HST pipeline procedures were employed for data reduction. The narrow-band and continuum images were acquired sequentially and did not require realignment. Flux calibration was performed using information available on the headers.
Subpixel imaging binning was employed to effectively oversample the Chandra point-spread function (PSF) and overcome the limitations of the ACIS instrumental pixel size. This method has been extensively used and validated in previous studies examining the subkiloparsec regions around nearby and obscured AGNs (e.g., Maksym et al. 2017 ; Fabbiano et al. 2018a ; Ma et al. 2021 ; Trindade Falcão 2023 ), demonstrating excellent agreement between reconstructed ACIS-S features and those imaged with higher spatial resolution instruments such as HST and VLA (e.g., Wang et al. 2011b ; Paggi et al. 2012 ; Maksym et al. 2019 ; Fabbiano et al. 2018b ). The Chandra PSF was simulated using ChaRT 9 and MARX . 10 This work uses a final Chandra scale of one-eighth of the native ACIS pixel.
In addition to the new Chandra and HST data sets, we analyze archival optical, radio, and X-ray observations of MCG-03-34-64, as listed in Table 1 . These data include 8.46 GHz radio imaging with VLA, optical continuum imaging with HST/ACS F814W, and X-ray spectra from Suzaku and XMM-Newton.
There are four additional archival Chandra observations with MCG-03-34-64 in the field of view (obs ids 27267, 27786, 7373, and 23690). However, three of these observations are not usable due to the galaxy being located at the very edge of the field (observations were optimized for the companion galaxy). The fourth available Chandra observation consists of a 7 ks snapshot (used in Miniutti et al. 2007 ), which has insufficient counts for meaningful imaging analysis.
3.1.1. hubble space telescope imaging.
The [O iii ] narrow-line region (NLR) in MCG-03-34-64 has a highly unusual morphology, featuring three distinct, and compact emission regions, as shown in Figure 1 . The NLR extends ∼2.3 kpc along the NE–SW direction. In the perpendicular direction (NW–SE), we observe three diffraction spikes characteristic of point sources, while one diffraction spike is observed along the NE–SW cone. These features suggest high concentrations of [O iii ] gas within a relatively small region, a rare occurrence in the local Universe (Fischer et al. 2018 ).
Figure 1. HST [O iii ] and F814W images of the central region of MCG-03-34-64. Note the prominent diffraction spikes present in the [O iii ] image.
Download figure:
To examine the overall structure of the NLR, we model the [O iii ] light distribution with GALFIT (Peng et al. 2002 , 2010 ). The modeling was performed with generic Sérsic profiles, and we allow all parameters to freely vary during the fitting process. The background level and standard deviation were determined from blank regions within the image's field of view.
The best-fit GALFIT model consists of four Sérsic components, one for each of the three peaks visible in the [O iii ] surface plot in the leftmost panel of Figure 2 , and an additional larger component to take into account the underlying fainter, more extended emission. In the second panel, we show a zoomed-in image of the [O iii ] emission, and mark the position of each Sérsic component corresponding to a strong peak of [O iii ] emission as green circles. The third panel of Figure 2 shows the best-fit GALFIT model, while the fourth panel shows the residual images from this best-fit model, with the different model components subtracted from the data.
Figure 2. First panel: surface plot of the [O iii ] flux in the HST/ACS image where three distinct sources are visible. Second panel: HST/ACS [O iii ] image showing the presence of three closely separated emission peaks. We mark the position of each Sérsic component for the emission peaks as green circles. Third panel: best-fit GALFIT model, using four Sérsic components. Fourth panel: residual image after subtraction of the best-fit GALFIT model.
Table 2 lists the best-fit model parameters. The strong [O iii ] peaks of emission are fit with Sérsic components with indices 0.41 ≤ n ≤ 0.51, indicating that they are similar to Gaussians ( n = 0.5), but in two cases show a slightly more centrally concentrated distribution. Given that these components have effective radii ∼2–3 times that of an unresolved source, we opted to not include a PSF component in the fitting model, since it is not expected to significantly change the results.
Component | R.A. | Decl. | / | P.A. (sky) | Flux | ||
---|---|---|---|---|---|---|---|
(J1200) | (J1200) | (arcsec) | (deg) | (erg s cm ) | |||
Sérsic I (northern [O iii]) | 13:22:24.4693 | −16:43:42.379 | 0.095 | 0.41 | 0.92 | 49.9 | 4.8 10 |
Sérsic II (central [O iii]) | 13:22:24.4561 | −16:43:42.515 | 0.101 | 0.51 | 0.64 | 32.3 | 2.2 10 |
Sérsic III (southern [O iii]) | 13:22:24.4549 | −16:43:42.737 | 0.160 | 0.44 | 0.53 | 24.9 | 3.2 10 |
Sérsic IV (fainter extended [O iii]) | 13:22:24.4625 | −16:43:42.576 | 0.508 | 2.91 | 0.59 | 34.3 | 4.6 10 |
Given the unique morphology of the optical emission observed in MCG-03-34-64 with HST, we examine other available multiwavelength observations (Table 1 ) to obtain a more comprehensive picture of this inner region.
Figure 3 shows the inner ∼200 pc region of MCG-03-34-64, as observed with Chandra/ACIS in different energy bands. The images are binned at one-eighth of the native pixel to use the full-resolution of the instrument in the high-count inner region, and processed with 1 kernel Gaussian smoothing.
Figure 3. Chandra/ACIS-S merged data set showing the inner 200 pc region of MCG-03-34-64 in different bands (one-eighth subpixel, and 1 kernel Gaussian smoothing). First panel: soft (0.3–3 keV) X-ray image. Second panel: 3–5 keV hard continuum image. Third panel: Fe K α (6.2–6.6 keV) Chandra image. We show the location of the two Fe K α centroids as blue circles. Fourth panel: 6–7 keV hard band Chandra image.
We measure nearly equal X-ray luminosities in the narrow 6.2–6.6 keV band from the Chandra image for both Fe K α peaks, L (6.2−6.6 keV) ∼ 3.2 ± 0.6 × 10 40 erg s −1 , for D ∼ 78 Mpc (e.g., de Grijp et al. 1992 ; Table 3 ).
Table 3. Chandra/ACIS-S Merged Data Set—Astrometry, Fluxes, and Luminosities of the Individual Fe K α Regions
Component | R.A. | Decl. | Counts | Flux | Luminosity |
---|---|---|---|---|---|
(J1200) | (J1200) | (photons) | (erg s cm ) | (erg s ) | |
Northern Fe K | 13:22:24.470 | −16:43:42.314 | 36 ± 6 | 4.6 10 | 3.2 ± 0.6 10 |
Central Fe K | 13:22:24.4584 | −16:43:42.643 | 37 ± 6 | 4.8 10 | 3.2 ± 0.6 10 |
Note. The luminosities are calculated for D = 78 Mpc.
To address concerns that the dual morphology might be a spurious detection due to smoothing on scales smaller than the Chandra PSF, we examine the individual Chandra observations (prior to merging) listed in Table 1 , in the Fe K α band (Figure 4 ). These images are binned at one-eighth of the native pixel and smoothed with a 1 kernel Gaussian. As shown, the dual morphology of the Fe K α band is indeed observed in all individual observations, prior to merging, confirming the robustness of the detection. The differences in surface brightness between the individual Chandra exposures seen in Figure 4 for the individual nuclei are most likely due to statistical noise.
The morphology of the 8.46 GHz radio continuum emission in MCG-03-34-64 is also analyzed, and shown in Figure 5 . The positions of the two radio centroids identified by Schmitt et al. ( 2001 ) in the inner region are shown as white circles (see their Table 2). The 8.46 GHz emission starts as a linear structure at the position of the northern radio centroid, extending ∼100 pc southwestward to the central radio peak, and then bending southward in the direction of the southern [O iii ] centroid (Figure 5 ). Table 4 lists the positions and fluxes of the individual radio components, as measured in Schmitt et al. ( 2001 ). The separation between the two centroids is 116 ± 14 pc.
Figure 5. VLA-A 8.46 GHz (3.6 cm) radio continuum image of MCG-03-34-64. White circles mark the position of the two radio peaks, and the [O iii ] centroids are shown in green. The image is shown in log scale.
Table 4. VLA-A 3.6 cm Radio Continuum Image Decomposition—Position and Fluxes of Individual Components
Component | R.A. | Decl. | Flux |
---|---|---|---|
(J1200) | (J1200) | (mJy) | |
Northern radio | 13:22:24.471 | −16:43:42.35 | 31.6 |
Central radio | 13:22:24.456 | −16:43:42.61 | 15.5 |
Note. From Schmitt et al. ( 2001 ).
We initially apply CIAO wavdetect 15 to the merged 0.3–7 keV Chandra image with a >5 σ detection threshold, detecting two faint sources near the edge of the chip array (via comparison with the Vizier source catalog). However, given their faintness, these are not suitable to use as a basis for astrometry correction.
We then create Chandra images in the narrow Fe K α band (6.2–6.6 keV), known to be dominated by nuclear emission in obscured sources (Fabbiano & Elvis 2024 ). Assuming that the radio emission in AGNs also originates from the innermost regions around the SMBH, we correct Chandra's absolute astrometry by aligning the emission peaks seen in the Fe K α band with those in the 8.46 GHz radio image. This alignment method has been used in similar studies, such as in Mrk 78 (Fornasini et al. 2022 ).
We apply a total shift of [Δx, Δy] = [0.1, 0.7] pixels to the Chandra/ACIS data, well within the absolute astrometry accuracy of the telescope. 16 Comparison with available HST observations confirms the accuracy of VLA's astrometry.
The overall spectral profile observed in the Chandra data is consistent across the earlier NuSTAR and XMM-Newton observations. All three spectra show an absorption feature at 6.8 keV, likely arising from Fe XXV absorption, and suggesting an outflow with v ∼ 5000 km s −1 , as noted in Miniutti et al. ( 2007 ). Below 3 keV, the soft X-ray emission is dominated by photoionized and collisionally ionized emission lines, from Ne, O, and Fe L ions (Miniutti et al. 2007 ).
We proceed to model the X-ray spectrum of MCG-03-34-64 with MYTorus (Murphy & Yaqoob 2009 ), a physically motivated model built to describe the interaction of the emission from an X-ray point-source with a surrounding, and homogeneous torus of cold neutral material.
We fit the joint XMM+NuSTAR X-ray spectrum with a source model of the form:
A × TBabs × [ xstar × MYTZ × zpowerlw +( C × ( MYTS + MYTL × gsmooth )+ zpowerlaw _ soft + soft _ emiss )], where TBabs describes the absorption of emission by the Galactic column density, xstar is the photoionized absorber described previously in Miniutti et al. ( 2007 ), [ MYTZ × zpowerlw] describes the intrinsic continuum in transmission absorbed by torus, MYTS is the scattered (reflected) toroidal component off Compton-thick matter, MYTL is the associated Fe/Ni K α /K β line emission, and gsmooth accounts for some Gaussian broadening of the MYTorus line emission, where the upper limit on the line width is σ < 65 eV. The soft X-ray components are zpowerlaw _ soft , which is an unabsorbed scattered power-law component, and soft _ emiss , which is the sum of the photo and collisionally ionized emission components described by Miniutti et al. ( 2007 ). A is the cross normalization factor between NuSTAR and XMM ( A = 1.20 ± 0.05) and C is the offset between reflected/line components and intrinsic continuum components ( C is frozen at 1). The results of the fitting are shown in Figure 6 (center and right panels).
Given the quality and resolution of the X-ray observations used in this work, the spectra and fitting models employed in our analysis account for emission within the entire inner region of MCG-03-34-64, and cannot be performed separately for the individual Fe K α peaks uncovered in the Chandra imaging data. In this case, the resulting configuration suggested by MYTorus requires one where one is looking along the edge (Compton-thin line of sight) of a very Compton-thick absorber overall, which obscures both Fe K α regions.
We also note that the difference observed between the summed Fe K α luminosities derived from the Chandra imaging, ∼6.4 × 10 40 erg s −1 , and the total Fe K α luminosity yielded by the spectral fitting with MYTorus , L (6.2−6.6 keV) = 1.0 × 10 41 erg s −1 , may be attributed to line absorption by the absorber, which in turn implies a higher intrinsic X-ray luminosity, as yielded by the results of the spectral fit.
The results presented in Section 3 reveal puzzling properties of the emission in MCG-03-34-64. Our imaging analysis identified three [O iii ]-emitting regions in the HST/ACS data, separated by 76 ± 8 and 79 ± 8 pc (Table 2 , Figure 2 ). In X-rays with Chandra/ACIS, two spatially resolved peaks of emission are observed in the narrow 6.2–6.6 keV Fe K α band, separated by 125 ± 21 pc (Table 3 , Figure 3 ). In the radio with VLA-A, Schmitt et al. ( 2001 ) previously identified two distinct radio cores in the 8.46 GHz continuum, separated by 116 ± 14 pc (Table 4 , Figure 5 ).
Figure 7 shows the Chandra/ACIS Fe K α image and the position of these multiwavelength centroids. The image is binned at one-eighth of the native ACIS-S pixel and smoothed with 1 kernel Gaussian.
Figure 7. Chandra/ACIS-S merged Fe K (6.2–6.6 keV) image of MCG-03-34-64 (one-eighth subpixel, and smoothed with 1 kernel Gaussian). Optical centroids from HST/ACS are shown in red, VLA-A 8.46 GHz centroids in white, and Chandra/ACIS Fe K centroids in blue. The circle sizes reflect uncertainties in the position of the centroids.
Table 5. Joint XMM and NuSTAR Spectral Fitting Results from MYTorus
(erg s ) | (erg s ) | (erg s ) | (erg s ) |
---|---|---|---|
1.0 10 | 2.1 10 | 1.5 10 | 4.5 10 |
Notes. We use a correction factor k = 30 (Vasudevan & Fabian 2007 ) to obtain the integrated bolometric luminosity in X-rays.
Our results reveal that the integrated observed fluxes are ≤3% of the integrated intrinsic flux in the band (Table 6 ), with the largest fraction originating from the central region. These fractions are consistent with scattered, hidden continuum (e.g., Pier et al. 1994 ), but could also include contributions from emission lines (e.g., Kraemer & Crenshaw 2000 ) and recombination continuum (Osterbrock & Robertis 1985 ). Therefore, it is unlikely that we will detect AGN continuum emission directly in the optical, and we cannot determine which of these regions harbors the AGN, given that all three regions are consistent with scatter continua from an active nucleus (but see below).
Table 6. [O iii ] Luminosities Calculated from the Measured [O iii ] Fluxes from Table 2 , and Considering a Distance of D = 78 Mpc
Component | ] | ||
---|---|---|---|
(erg s ) | (erg s ) | (erg s cm ) | |
Northern [O iii] | 3.5 10 | 1.6 10 | 8.3 10 |
Central [O iii] | 1.6 10 | 7.3 10 | 1.2 10 |
Southern [O iii] | 2.3 10 | 1.0 10 | 6.4 10 |
Sérsic | 3.3 10 | 1.5 10 | ... |
Total | 1.1 10 | 4.8 10 | ... |
Note We use a correction factor c = 454 (Lamastra et al. 2009 ) to calculate the bolometric luminosity in each [O iii ] region. We also show the measured F814W fluxes for each emitting region.
The high fluxes and luminosities found in Section 3 for individual emission regions in the optical, X-ray, and radio bands support the presence of an AGN in this system. However, pinpointing the AGN's location is more challenging. We discuss possible interpretations for the system's configuration, based on our results and the limitations of the data.
One interpretation is that the active nucleus is located at the position of the northern centroids ([O iii ], Fe K α , and radio; see Figure 7 ), based on the fluxes of individual components (Tables 2 , 3 , and 4 ). In this single AGN scenario, the remaining emission centroids (central Fe K α , [O iii ] and radio centroids, and southern [O iii ]) may arise from the interaction between the AGN and the interstellar medium (ISM). This would manifest as a mix of photoionized and collisionally ionized (shocked) gas from an extended NLR, similar to NGC 3393 (e.g., Maksym et al. 2016 ). Such an interpretation is consistent with previous spectral fitting results for this galaxy, which indicate a mix of photoionized and shock-ionized gas in the soft X-ray emission (Miniutti et al. 2007 ). Similarly, it is possible that the AGN in this system is located at the position of the central [O iii ], Fe K α , and radio peaks, while the remaining multiwavelength centroids may be attributed to AGN–ISM shock emission.
Following the discussion in Section 4.2.1 , the high Fe K α luminosities (Table 3 ), and the high energies required for the production of such line emission suggest that both Fe K α regions could be powered by an active SMBH. In this scenario, the northern emission centroids would pinpoint the location of one AGN, while the central emission centroids (radio, Fe K α , and optical) may be associated with a second active SMBH in this system (given the high fluxes found for the central optical region in the F814W continuum band; Table 6 ). The distances measured between the different centroids attributed to each AGN are consistent across different wave bands (Table 7 ), supporting the dual AGN scenario.
Table 7. Distances between Multiwavelength Centroids Found in This Work: HST/ACS, VLA-A, and Chandra/ACIS-S (Fe K α )
Components | Distance | Distance | Distance Range |
---|---|---|---|
(arcsec) | (pc) | (pc) | |
Northern [O iii] → central [O iii] | 0.233 ± 0.02 | 79 ± 8 | 71–87 |
Central [O iii] → southern [O iii] | 0.223 ± 0.02 | 76 ± 8 | 68–84 |
Northern [O iii] → southern [O iii] | 0.413 ± 0.01 | 140 ± 5 | 135–145 |
Northern radio → central Radio | 0.338 ± 0.04 | 116 ± 14 | 102–130 |
Northern Fe K → central Fe K | 0.369 ± 0.08 | 125 ± 21 | 104–146 |
Central [O iii] → central Fe K | 0.132 ± 0.06 | 45 ± 21 | 24–66 |
Southern [O iii] → central Fe K | 0.107 ± 0.06 | 36 ± 21 | 15–57 |
In this scenario, the southern [O iii ] region may arise from collisionally ionized emission in the ISM. Shock emission from jet–ISM interaction at the southern optical centroid location is supported by (1) the morphology of the radio emission at the central radio peak, which is observed to bend southward (Schmitt et al. 2001 ), in the direction of the southern [O iii ] peak (see Figures 5 and 3 , and Section 3.1.3 ); and (2) the morphology of the Chandra 0.3–3 keV (soft) emission, which is also observed to bend southward in the direction of the southern [O iii ] centroid (see Figure 3 , and Section 3.1.3 ). The lack of a corresponding southern radio or hard X-ray counterpart is consistent with the hypothesis that the northern and central [O iii ] centroids are powered by individual AGNs.
The dual AGN scenario is strengthened by the consistent values between the estimated bolometric luminosities derived from [O iii ] and X-rays (Tables 5 and 6 ), and the detection of nearly equal Fe K α emission peaks in the Chandra image, a powerful tool for identifying and confirming dual AGN systems (De Rosa et al. 2022 ). In the 3–5 keV Chandra image (Figure 3 ), the northern nucleus appears brighter than the central nucleus, although some extended emission is observed toward the central nucleus in this band. The column densities in the transmission of the two nuclei may not be the same, i.e., the AGN located at the central Fe K α region could have a higher absorbing column and appear fainter at lower energies. A higher contribution from the photoionized+thermal extended soft X-ray gas is expected at these lower energies. Given the resolution of the analyzed X-ray data, performing a separate spectral analysis of each individual Fe K α region is currently impractical.
We analyze new HST/ACS and Chandra/ACIS observations of the nearby Seyfert galaxy MCG-03-34-64, along with archival HST/ACS, XMM-Newton/Epic-pn, NuSTAR, and VLA-A data sets. Our analysis reveals the following:
In X-rays with Chandra: Two spatially resolved emission centroids are detected in the 6.2–6.6 keV Fe K α image, separated by 125 ± 21 pc. These peaks are evident in individual exposures and the merged data set. The northern and central Fe K α regions have 36 ± 6 and 37 ± 6 counts in the narrow 6.2–6.6 keV band, respectively, corresponding to ≥6 σ detections, and nearly equal Fe K α luminosities, L (6.2−6.6 keV) ∼ 3.2 ± 0.6 × 10 40 erg s −1 .
In the radio with VLA: Two emission regions are observed in the 3.6 cm VLA continuum image (Schmitt et al. 2001 ), spatially colocated with the northern and central Fe K α and [O iii ] regions.
We propose two possible physical interpretations of our results, and discuss these in the context of our analysis:
1. The "single AGN+shocked ISM" scenario, which proposes the existence of a single active nucleus in the system, while the remaining multiwavelength centroids may be attributed to the interaction of the ISM with the radio jet in the NLR.
This scenario is strengthened by:
a. Previous X-ray studies on this source, which find evidence for a mix of collisionally and photoionized X-ray gas in the NLR (Miniutti et al. 2007 ).
This scenario is challenged by:
b. The high Fe K α luminosities derived for individual regions and the energies required for the production of such line emission.
2. The "dual AGN+shocked ISM" scenario, which proposes the existence of a dual SMBH pair in this system separated by just 125 ± 21 pc.
a. The detection of two spatially resolved Fe K α regions in the Chandra imaging data, with high individual luminosities (Table 3 ).
b. The detection of three very bright and compact (<60 pc diameter) [O iii ]-emitting regions in the HST imaging data, and the respective individual bolometric luminosities (Table 6 ).
c. The detection of spatially coincident Fe K α , radio, and [O iii ] centroids at the northern and central regions. This is the first time spatially resolved, multiwavelength emission centroids in X-rays, radio, and optical are detected colocated in a nearby candidate dual AGN. For comparison, the recent study of Koss et al. ( 2023 ), which identified the presence of a dual AGN system separated by ∼230 pc in UGC 4211, detected colocated optical (HST F814W, MUSE AO [O iii ], and H α ), NIR (Keck J and K'), and submillimeter (Atacama Large Millimeter/submillimeter Array continuum at ∼230 GHz) centroids at the position of the two nuclei, but with no confirmation from X-rays or radio observations.
In summary, although we cannot definitively confirm or exclude the physical scenarios presented here, identification of the two nuclei in a deeper Chandra exposure would help to confirm a possible dual black hole system in this galaxy. Analysis of gas kinematics in the nuclear region of MCG-03-34-64 is crucial to determine the nature of the observed structures. Kinematic information obtained with HST/STIS long-slit spectroscopy could reveal disturbed kinematics expected from either the individual outflows of two SMBHs or the highly disturbed kinematics resulting from the merger environment. This information cannot be obtained from the archival X-Shooter data and requires the resolution of HST to probe the ∼100 pc region of interest.
https://ned.ipac.caltech.edu/
https://cxc.cfa.harvard.edu/ciao/
https://cxc.cfa.harvard.edu/ciao/PSFs/chart2/
https://space.mit.edu/cxc/marx/
https://cxc.cfa.harvard.edu/ciao/ahelp/specextract.html
https://heasarc.gsfc.nasa.gov/lheasoft/ftools/fhelp/mathpha.html
https://heasarc.gsfc.nasa.gov/lheasoft/ftools/fhelp/addrmf.html
https://heasarc.gsfc.nasa.gov/lheasoft/ftools/fhelp/addarf.html
https://cxc.cfa.harvard.edu/ciao/ahelp/wavdetect.html
https://cxc.cfa.harvard.edu/cal/ASPECT/celmon/
IMAGES
VIDEO
COMMENTS
Publishing in an Elsevier journal starts with finding the right journal for your paper. We have tools, resources and services to help you at each stage of the publication journey to enable you to research, write, publish, promote and track your article.
Communicating research findings is an essential step in the research process. Often, peer-reviewed journals are the forum for such communication, yet many researchers are never taught how to write a publishable scientific paper. In this article, we explain the basic structure of a scientific paper and describe the information that should be included in each section. We also identify common ...
To Publish a Research Paper follow the guide below: Conduct original research: Conduct thorough research on a specific topic or problem. Collect data, analyze it, and draw conclusions based on your findings. Write the paper: Write a detailed paper describing your research.
In this article, intended for doctoral students and other young scholars, I identify common pitfalls and offer helpful solutions to prepare more impactful papers. While there are several types of research articles, such as short communications, review papers and so forth, these guidelines focus on preparing a full article (including a literature review), whether based on qualitative or ...
Abstract This article provides an overview of writing for publication in peer-reviewed journals. While the main focus is on writing a research article, it also provides guidance on factors influencing journal selection, including journal scope, intended audience for the findings, open access requirements, and journal citation metrics. Finally, it covers the standard content of a scientific ...
Successfully publishing a research paper in international journals is a key part of a researcher's work and can shape the trajectory of their careers. This not only helps advance the knowledge in a researcher's field of work but also helps them build networks and even secure funding for new research in the long run. However, irrespective of the discipline, a beginner with even a brilliant ...
Communicating research findings is an essential step in the research process. Often, peer-reviewed journals are the forum for such communication, yet many researchers are never taught how to write a publishable scientific paper. In this article, we explain ...
How to publish an article? - Step by step If you plan to submit an article to one of our journals, or have any questions during the publication process, this helpdesk will guide you through manuscript submission, production and the services you can expect after your article's publication.
The publication process explained. The path to publication can be unsettling when you're unsure what's happening with your paper. Learn about staple journal workflows to see the detailed steps required for ensuring a rigorous and ethical publication. Your team has prepared the paper, written a cover letter and completed the submission form.
How to write effectively for international journals Use modern tools to manage research literature, analyse published articles and find language teachers to improve manuscripts for publication.
Submitting your paper. The Instructions for Contributors document for each journal will explain the process for submitting your paper to that particular title, including guidance on additional information you should include alongside your manuscript. A growing proportion of our journals now use an online submission system - in most cases ...
International Journal encourages authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained.
How to select the journal to publish your research in Choosing which journal to publish your research in can seem like an overwhelming task. So, for all the details of how to navigate this important step in publishing your research paper, take a look at our choosing a journal guide.
Publishing a research paper immediately requires careful planning and swift execution. Select a Reputable Journal: Identify a journal that aligns with your research's scope and significance. Aim for well-regarded, peer-reviewed publications. Prepare Your Manuscript: Ensure your paper adheres to the journal's guidelines for formatting ...
7. Promote the paper: Once the paper has been accepted for publication, it is important to promote it to increase its visibility and impact. This can be done by sharing the paper on social media, presenting it at conferences, and emailing colleagues and peers in the field. In conclusion, publishing a research paper in an international journal ...
Publishing a research paper in a peer-reviewed journal allows you to network with other scholars, get your name and work into circulation, and further refine your ideas and research. Before submitting your paper, make sure it reflects all the work you've done and have several people read over it and make comments. Keep reading to learn how you can choose a journal, prepare your work for ...
How to publish a paper in scholarly journal, academic journal & international journal. The IJSER is an open access peer reviewed international journal to publish high quality research papers.
PDF | This is a book version of a course taught to graduate students on how to publish in international journals. | Find, read and cite all the research you need on ResearchGate
How to Publish a Research Paper Publishing a research paper or getting it published in an academic journal can be one of the most fulfilling accomplishments in your academic career. You've spent countless hours learning, researching, thinking and writing, and now you get to share your knowledge with others who share your interests and passion … How to Publish a Research Paper: A Step-by ...
This article is all about How to publish a paper in international journal. Learn the complete procedure about journal publication steps and..
The research paper publication process starts with the submission of your research paper via online submission. Authors can submit original research papers, case studies, survey paper, exntended versions of previously published papers in international journals & conferences. The peer review process usually complete within 09-12 days time ...
The articles of the International Journal of Management Science and Business Administration are available free of charge both to individual users and organizations. This means users can read, download, copy, share, print out, or reference to the texts of the journal without having to get permission from the authors or publishers.
One way we measure safety is by testing how well our model continues to follow its safety rules if a user tries to bypass them (known as "jailbreaking"). On one of our hardest jailbreaking tests, GPT-4o scored 22 (on a scale of 0-100) while our o1-preview model scored 84. You can read more about this in the system card and our research post.
Publishing Workshop: How to Get Your Addiction Research Published in Peer-Reviewed Journals. In this workshop, Adam Gordon and Casy Calver from the International Society of Addiction Journal Editors (ISAJE) highlighted three essential aspects to publishing addiction research: choosing a journal, submission and peer review, and authorship.
The American Astronomical Society (AAS), established in 1899 and based in Washington, DC, is the major organization of professional astronomers in North America.Its membership of about 7,000 individuals also includes physicists, mathematicians, geologists, engineers, and others whose research and educational interests lie within the broad spectrum of subjects comprising contemporary astronomy.